eDiagnosis(SZ:002932) Xin Lang Cai Jing·2025-11-12 05:50Core Viewpoint - Mingde Biological's stock has shown a mixed performance in recent trading sessions, with a year-to-date increase of 14.50% and a notable decline of 8.77% over the past 60 days [1] Financial Performance - For the period from January to September 2025, Mingde Biological reported revenue of 227 million yuan, reflecting a year-on-year growth of 0.53%. However, the net profit attributable to shareholders decreased significantly by 83.30% to 13.52 million yuan [2] - Cumulatively, since its A-share listing, Mingde Biological has distributed a total of 1.76 billion yuan in dividends, with 875 million yuan distributed over the past three years [3] Shareholder Structure - As of October 31, 2025, the number of shareholders for Mingde Biological decreased by 2.27% to 23,100, while the average number of circulating shares per person increased by 2.32% to 6,763 shares [2] - The top ten circulating shareholders include notable funds such as GF Value Core Mixed A and Rongtong China Wind 1, with some new entrants and changes in holdings among the top shareholders [3] Market Activity - On November 12, Mingde Biological's stock price rose by 2.01% to 19.77 yuan per share, with a trading volume of 39.1 million yuan and a turnover rate of 1.28% [1] - The stock experienced a net outflow of 204,300 yuan from major funds, while large orders showed mixed buying and selling activity [1] Business Overview - Mingde Biological, established on January 28, 2008, specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, with a revenue composition of 65.04% from in vitro diagnostic products, 21.91% from third-party medical testing, and 13.05% from agency and other businesses [1] - The company operates within the pharmaceutical and biological industry, specifically in the medical device and in vitro diagnostic sectors [1]